The Menopause Society

A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.

In this video from The Menopause Society Annual Meeting, Lauren Streicher, MD, talks about what to ask your patients about sexual function.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, insulin resistance was significantly reduced among postmenopausal women receiving hormone therapy vs placebo.

At the 2024 Menopause Society meeting, JoAnn Pinkerton, MD, highlighted phase 3 long-term safety data of elinzanetant from the OASIS 3 trial.

A discussion of vasomotor symptoms and the potential benefits of elinzanetant with Nanette Santoro, MD, from The Menopause Society annual meeting in Chicago, Illinois.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, 23% of patients with breast arterial calcifications on a mammogram had atherosclerotic cardiovascular disease, vs 13.9% without.

A new study presented at the 2024 Annual Meeting of the Menopause Society found cognitive behavioral therapy can effectively address sexual concerns during menopause, improving overall well-being.

Nanette Santoro, MD, and Lauren Streicher, MD, MSCP, briefly highlight why they feel the annual Menopause Society is a great place for learning and collaboration.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, the prevalence of Alzheimer’s disease was significantly increased among women with prior trauma.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, women with certain adverse outcomes during pregnancy had an increased risk of cardiovascular disease later in life.

Female veterans with PTSD are twice as likely to experience early menopause and related health risks, according to a study presented at the 2024 Annual Meeting of The Menopause Society.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, 59% of nocturnal hot flashes occurred during the second half of the night, a time linked to increased cardiovascular disease risk.

A study presented at the 2024 Annual Meeting of The Menopause Society, found that women who reported physical intimate partner violence also demonstrated decreased working memory performance over time.

Data presented at the 2024 Annual Meeting of The Menopause Society highlighted greater reductions in hot flash severity among women receiving clinical hypnosis compared to those receiving cognitive behavioral therapy.

This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.

James A Simon, MD, discusses the link between hot flashes and poor sleep quality, and how clinicians can help their patients manage sleep disorders.

Steven R. Goldstein, MD, discusses holes in clinicians' understanding of the endometrium, and how these knowledge gaps can be remedied.

Michael E. Lewiecki, MD, discusses risk factors of osteoporosis in midlife women, and how clinicians can measure and manage bone health.

Mary Jane Minkin, MD, FACOG, MSCP, discusses key takeaways from The Menopause Society 2023 Annual Meeting, held in Philadelphia, Pennsylvania from September 27-30.

Barbara A. Dehn, NP, Vice President of Women’s Health at Peppy Health, discusses topics presented at The Menopause Society which will help her in her practice.

Nanette F. Santoro, MD, chair of OBGYN at the University of Colorado School of Medicine, discusses new research on fezolinetant as a nonhormone method for managing hot flashes at the 2023 Menopause Society Annual Meeting.

In a recent study, increased hair cortisol levels were effective at measuring worsened cognitive health in perimenopausal women.

In a recent study, hot flashes were indicated to be an underlying risk factor for cardiovascular disease.

In a recent study, variations in physiology during aging were found between male and female participants.

Commons forms of osteoarthritis, as well as prevention methods, were discussed at The Menopause Society 2023 annual conference.

The most recommended and non-recommended methods of nonhormone therapy for treatment of vasomotor symptoms were discussed at The Menopause Society 2023 Annual Conference.

Advancements in technology used to measure bone health in postmenopausal women were discussed at the Menopause Society 2023 Annual Meeting.

A recent study measuring sexual functioning in women with post-traumatic stress disorder was discussed at The Menopause Society 2023 Annual Meeting.

Genevieve Neal-Perry, MD, discusses how fezolinetant is effective for treating vasomotor symptoms.

In a recent study highlighted at the Menopause Society 2023 Annual Meeting, a correlation was found between the number of hot flashes experienced and the risk of Alzheimer’s disease among perimenopausal and postmenopausal women.